BioCardia (NASDAQ:BCDA) Director Simon Stertzer Purchases 70,200 Shares

BioCardia, Inc. (NASDAQ:BCDA) Director Simon Stertzer acquired 70,200 shares of the business’s stock in a transaction that occurred on Monday, June 22nd. The shares were purchased at an average price of $0.92 per share, with a total value of $64,584.00. Following the completion of the transaction, the director owned 127,338 shares of the company’s stock, valued at $117,150.96. The trade was a 122.86% increase in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.

BioCardia Price Performance

Shares of BCDA stock opened at $1.06 on Thursday. The company has a market capitalization of $12.06 million, a PE ratio of -1.16 and a beta of 0.51. The firm’s 50-day moving average is $1.02 and its two-hundred day moving average is $1.17. BioCardia, Inc. has a 12 month low of $0.78 and a 12 month high of $2.45.

BioCardia (NASDAQ:BCDA) last posted its quarterly earnings results on Friday, May 15th. The company reported ($0.21) earnings per share for the quarter, missing the consensus estimate of ($0.17) by ($0.04). Sell-side analysts forecast that BioCardia, Inc. will post -0.76 EPS for the current year.

Hedge Funds Weigh In On BioCardia

Institutional investors have recently bought and sold shares of the company. Cetera Investment Advisers acquired a new stake in shares of BioCardia during the second quarter worth about $40,000. Geode Capital Management LLC grew its holdings in shares of BioCardia by 70.4% in the fourth quarter. Geode Capital Management LLC now owns 66,003 shares of the company’s stock valued at $83,000 after purchasing an additional 27,263 shares in the last quarter. Finally, DRW Securities LLC purchased a new stake in BioCardia during the 4th quarter worth approximately $72,000. 20.57% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on BCDA shares. HC Wainwright reiterated a “buy” rating and issued a $25.00 price objective on shares of BioCardia in a research report on Tuesday, June 9th. Weiss Ratings restated a “sell (e+)” rating on shares of BioCardia in a research report on Monday, April 20th. One research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $25.00.

About BioCardia

BioCardia, Inc is a clinical-stage biotechnology company dedicated to developing novel cell-based therapies for patients with cardiovascular disease. The company’s core focus lies in advancing regenerative medicine approaches that address both chronic heart failure and acute myocardial infarction. BioCardia leverages proprietary delivery technologies to optimize the targeted administration of therapeutic cells directly into the heart muscle.

The company’s flagship products include the Helix Transendocardial Delivery System and the CardiAMP Cell Therapy System.